首页 | 本学科首页   官方微博 | 高级检索  
     

西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性
引用本文:王世广,司旭艳,李晓婷,李登云,王丽君,王鹏. 西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性[J]. 解剖学报, 2019, 50(6): 754-760. DOI: 10.16098/j.issn.0529-1356.2019.06.009
作者姓名:王世广  司旭艳  李晓婷  李登云  王丽君  王鹏
作者单位:郑州工业应用技术学院医学院医学机能教研室,河南新郑,451150;郑州工业应用技术学院临床基础教研室,河南新郑,451150;郑州大学护理学院基础教研室,郑州,450052
基金项目:国家自然科学基金资助项目;河南省高等学校重点科研项目;河南省高等学校重点科研项目;河南省卫生与计划生育委员会医学教育研究课题
摘    要:
目的 观察西达本胺(CDM)能否影响人慢性髓系白血病耐药株K562/ADM细胞对柔红霉素(DNR)的敏感性,并探讨其可能的分子机制。方法 体外常规培养K562细胞和K562/ADM细胞,给予不同剂量CDM和(或)DNR处理48 h后,采用细胞计数试剂盒8(CCK-8)法检测CDM与DNR对K562和K562/ADM细胞的毒性作用,采用Chou-Talalay中效分析法对两药的联合效应进行评价,采用流式细胞术检测细胞增殖、细胞周期和凋亡,采用Western blotting方法检测组蛋白2AX(H2AX)、γH2AX(Ser139)、共济失调毛细血管扩张征突变基因(ATM)、p-ATM(Ser1981)、乳腺癌易感蛋白l(BRCA1)和p-BRCA1(Ser1524)的蛋白表达水平。 结果 DNR可剂量依赖性地抑制K562/ADM细胞活力(P<0.05),半数抑制浓度(IC50)为11.76 μmol/L,耐药倍数为18.09;CDM可协同增强DNR对K562/ADM细胞的抑制作用置信区间(CI)(CI<1),反转倍数为8.11;与对照组相比,DNR组细胞增殖率显著降低(P<0.05),G2/M期细胞比例和凋亡率明显升高(P<0.05),而无毒剂量的CDM可协同增强DNR引起的细胞增殖抑制、G2/M期阻滞和细胞凋亡(P<0.05);耐药株K562/ADM细胞中ATM和BRCA1蛋白表达水平显著高于其亲代K562细胞(P<0.05);DNR可上调K562/ADM细胞中H2AX、ATM和BRCA1蛋白的磷酸化水平(P<0.05);CDM与DNR联用可使γH2AX蛋白水平进一步升高,但p-ATM和p BRCA1蛋白水平的变化则相反(P<0.05)。 结论 CMD可反转K562/ADM细胞对DNR的耐药性,这可能与上调H2AX蛋白的磷酸化水平以及下调ATM和BRCA1蛋白的磷酸化水平有关。

关 键 词:西达本胺  柔红霉素  K562/ADM细胞  乳腺癌易感蛋白1  组蛋白2AX  流式细胞术  
收稿时间:2018-10-29
修稿时间:2019-05-22

Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin
WANG Shi-guang SI Xu-yan LI Xiao-ting LI Deng-yun WANG Li-jun WANG Peng. Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin[J]. Acta Anatomica Sinica, 2019, 50(6): 754-760. DOI: 10.16098/j.issn.0529-1356.2019.06.009
Authors:WANG Shi-guang SI Xu-yan LI Xiao-ting LI Deng-yun WANG Li-jun WANG Peng
Affiliation:1.Department of Medical Function, Medical College, Zhengzhou University of Industrial Technology, He’nan Xinzheng 451150, China; 2.Department of Clinical Foundation, Medical College, Zhengzhou University of Industrial Technology, He’nan Xinzheng 451150, China; 3.Department of Basic, College of Nursing, Zhengzhou University, Zhengzhou 450052, China
Abstract:
Objective To investigate whether chidamide (CDM) could influence the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin (DNR) and its possible mechanism. Methods The K562 and K562/ADM cells were cultured in vitro and treated with CDM and(or) DNR for 48 hous, and then the cell viability was measured by cell counting kit-8(CCK-8) assay. The proliferation, cell cycle and apoptosis were analyzed by flow cytometry. Western blotting was performed to measure the protein levels of histon 2AX(H2AX), γH2AX (Ser139), ataxia telangiectasia mutated gene (ATM), p-ATM (Ser1981), breast cancer susceptibility protein 1(BRCA1), and p-BRCA1 (Ser1524). Results DNR remarkably inhibited the cell activity of K562/ADM cells in dose-dependent manner with a half maximal inhibitory concentration(IC50) value of 11.76 μmol/L, and the resistant factor was 18.09. Co-treatment with CMD and DNR produced a synergistic effect confidence interval(Cl)(CI<1) with a reversal fold of 8.11. DNR remarkably inhibited proliferation (P<0.05), induced G2/M phase arrest and apoptosis (P<0.05), these effects were enhanced under non-toxic concentration of CMD (P<0.05). K562/ADM cells had a significantly higher protein levels of ATM and BRCA1 than K562 cells (P<0.05). DNR significantly up-regulated the protein levels of γH2AX, p-ATM and p-BRCA1 (P<0.05), and the protein level of γH2AX appeared higher in the combination group compared to DNR alone (P<0.05); however, the co-treatment with CMD and DNR induced a decreased expression of p-ATM and p BRCA1 than the DNR alone (P<0.05). Conclusion CDM may enhance the sensibility of K562/ADM cells to DNR by up-regulating the protein level of γH2AX, and down-regulating the protein levels of p-ATM and p-BRCA1.
Keywords:Chidamide   Daunorubicin   K562/ADM cell   Breast cancer susceptibility protein 1   Histon2AX   Flow cytomertry  Human  
本文献已被 万方数据 等数据库收录!
点击此处可从《解剖学报》浏览原始摘要信息
点击此处可从《解剖学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号